BioHarvest Sciences Inc. Common Stock Q3 2026 Earnings Call Summary Moby Intelligence Thu, November 12, 2026 at 1:15 PM EST 3 min read NVDA -4.48% BHST 0.00% Trade NVIDIA on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management characterized the third quarter as a 'deliberate transition' period, prioritizing cash preservation and liquidity over aggressive top-line growth.
The company scaled back lower-return customer acquisition activities for the VINIA product line to improve long-term contribution margins and overall business economics.
CDMO resources were strategically reallocated toward advanced programs with near-term manufacturing potential, specifically prioritizing the rare fragrance project over other development projects.
Consolidated gross margin compression to 54% was primarily driven by a revenue mix shift toward the product business and a lower contribution from high-margin CDMO development fees.
Operating expenses were impacted by accelerated technology development expenditures required to meet the timeline of the newly signed fragrance supply agreement.
Management is aligning capital allocation and operating expenses with commercial priorities, aiming to translate existing technical capabilities into stronger cash economics.
Management expects the benefits of the VINIA marketing pivot to become evident in the first quarter of 2027 as the company shifts toward more efficient customer acquisition channels.
The rare fragrance program is projected to generate $20 million to $30 million in revenue across 2027 and 2028, subject to successful development and production readiness.
Manufacturing capacity expansion will be executed in gradual phases aligned with demonstrated demand to minimize cash burn and preserve liquidity.
Strategic priorities for 2027 include completing development for the Saffron compound and the Tate & Lyle sweetener molecule, alongside licensing existing molecule assets.
Fixed operating costs are expected to decrease in 2027 through the planned consolidation of development sites, while cash will also be preserved by reducing the speed of manufacturing capacity expansion and capping capital expenditures.
The company signed its first exclusive manufacturing and supply agreement for a rare fragrance ingredient, targeting a high-value market where premium grades exceed tens of thousands of dollars per kilogram.
Management revised full-year 2026 revenue guidance downward to $32 million to $33.5 million to reflect the impact of the strategic resource reallocation and marketing shifts.
A share buyback program was initiated, though management characterized it as 'very moderate' and not intended to conflict with the primary goal of cash preservation.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Management explained that the buyback decision was made when resources were deemed adequate and the program remains 'very moderate' in scale.
The company does not intend to deploy significant financial resources for buybacks that would result in an accelerated depletion of cash.
Revenue is expected from three sources: ongoing development fees for sweetener and Saffron programs, molecule licensing, and fragrance manufacturing.
Manufacturing revenue for the fragrance program is targeted for the second half of 2027, depending on the completion of the development phase.
Cash preservation will primarily come from slowing the pace of manufacturing capacity expansion rather than cutting critical R&D programs.
Management is focusing technical resources on the fragrance program due to its estimated $150 million to $200 million potential over the next five years.
Management intends to cap total capital expenditures for 2027 at below $5 million.
This limit is part of a broader strategy to maximize existing facility utilization before committing to significant new capacity spending.
